Page 11 - Dr Reddy's Laboratories
Dr Reddy's Q4 net profit rises 3-fold to Rs 337.6 cr
Shares of the company were trading 0.14% down at Rs 2,588.75 on BSE
 "Dr Reddy's Q4 net profit rises 3-fold to Rs 337.6 cr")
Dr Reddy's hits 52-week low ahead of Q4 results
Since Feb 3, post Q3FY17 results, the stock declined 19% as compared to 7% rise in Sensex.
 "Dr Reddy's hits 52-week low ahead of Q4 results")
Dr Reddy's gains as USFDA completes inspection of Srikakulam SEZ unit
The stock was up 3% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex at 09:30 am.
Dr Reddy's Srikakulam unit receives Form 483 with 2 observations
Srikakulam unit is among three facilities that received warning letter from US FDA in Nov 2015
Dr Reddy's unit fails to clear US FDA audit
The US drugs regulator had issued a warning letter to three of firm manufacturing facilities
No claims for monetary damages: Dr Reddy's on patent infringement
Claims sought injunctive relief to prohibit manufacturing, use, import, sale of palonosetron product prior to expiration
 "No claims for monetary damages: Dr Reddy's on patent infringement")
Dr Reddy's hits 52-week low on patent infringement
The stock hit a 52-week low of Rs 2,799, down 4% on the National Stock Exchange in intra-day trade.
Dr Reddy's launches generic drugs in France, to expand operations in Europe
The company recently launched select products of its hospital portfolio in Italy and Spain
Dr Reddy's Q3 net profit dips by 19% to Rs 470 cr
Revenues dropped by 7% to Rs 3,707 crore y-o-y
 "Dr Reddy's Q3 net profit dips by 19% to Rs 470 cr")
USFDA to re-inspect Dr Reddy's plants by March
The company received a warning letter from the USFDA on November 5, 2015, for specific violations
Dr Reddys Lab hits three-month high
In past three-trading sessions, post QFY17 results the stock gained 7% as compared to 1.62% decline in Sensex
 "Dr Reddys Lab hits three-month high")
Dr Reddy's announces collaboration with Gland Pharma for US market
Combined sale of branded and generic versions of the products in the US is approximately $1 billion
Dr Reddy's Q2 net down 60% at Rs 308 cr as US generic sales plunge
Declining US sales had a bearing on the company's revenues and profitability
 "Dr Reddy's Q2 net down 60% at Rs 308 cr as US generic sales plunge")
Poor sales in North America plunge Dr Reddy's Q2 profit; down 60% to Rs 31 cr
Shares of DRL were trading at Rs 3,115.60 on BSE during the morning trading hour, up 0.84 per cent from previous close
Dr Reddy's launches anti-epileptic medicine in the US market
The product is a generic equivalent of Lamictal ODT in the US; Lamictal ODT is a registered trademark of GSK group
 "Dr Reddy's launches anti-epileptic medicine in the US market")
Is Dr Reddy's Lab out of the woods?
Faster pace of product launches can drive recovery in growth, but for regulatory clearances
 "Is Dr Reddy's Lab out of the woods?")
Dr Reddy's to market three more Amgen products in India
The drugs provide treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis
Dr Reddy's listed on Dow Jones Sustainability Indices 2016
The Dow Jones Sustainability Indices is a leading global benchmark for corporate sustainability
A prescription for success: Dr Reddy's makes pharma packaging more patient-friendly
Redesigns its syrup bottles and blister packs
 "A prescription for success: Dr Reddy's makes pharma packaging more patient-friendly")
Dr Reddy's completes acquisition of Teva's US portfolio of 8 products
Pharma major expects some products to add to its topline in 2018; products were being divested by Teva as a condition to close acquisition with Allergan
